- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cartesian Therapeutics Inc (RNAC)
Cartesian Therapeutics Inc stock price live, this page displays NASDAQ RNAC stock exchange data. View the RNAC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cartesian Therapeutics Inc real time stock price chart below.
What Is the Cartesian Therapeutics Inc Stock Price Today?
The Cartesian Therapeutics Inc stock price today is 7.360.
What Is the Stock Symbol for Cartesian Therapeutics Inc?
The stock symbol for Cartesian Therapeutics Inc is "RNAC."
What Stock Exchange Does Cartesian Therapeutics Inc Trade On?
Cartesian Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Cartesian Therapeutics Inc a Good Stock to Buy?
Determining whether Cartesian Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RNAC quote. (ISIN: US8162123025)
What Is the Cartesian Therapeutics Inc Stock Price Today?
The Cartesian Therapeutics Inc stock price today is 7.360.
What Is the Stock Symbol for Cartesian Therapeutics Inc?
The stock symbol for Cartesian Therapeutics Inc is "RNAC."
What Stock Exchange Does Cartesian Therapeutics Inc Trade On?
Cartesian Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Cartesian Therapeutics Inc a Good Stock to Buy?
Determining whether Cartesian Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RNAC quote. (ISIN: US8162123025)
7.360
-0.060(-0.81%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.360
7.576
52 wk Range
5.600
13.210
Earnings results expected in 7 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.3607.576
52 wk Range
5.60013.210
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RNAC Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
34.571
Upside
+369.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 8K Cartesian Therapeutics Inc For: 9 June- Investing.com
- Form 8K Cartesian Therapeutics Inc For: 9 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 34.571
(+369.72% Upside)
Earnings
Latest Release
Apr 30, 2026
EPS / Forecast
-1.46 / -0.95
Revenue / Forecast
78K / --
Compare RNAC to Peers and Sector
Metrics to compare | RNAC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRNACPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −2.8x | −0.3x | |
PEG Ratio | 0.01 | −0.09 | 0.00 | |
Price/Book | −1.5x | 2.4x | 2.6x | |
Price / LTM Sales | 122.8x | 5.3x | 2.9x | |
Upside (Analyst Target) | - | 372.4% | 56.7% | |
Fair Value Upside | Unlock | 26.3% | 10.2% | Unlock |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Cartesian Therapeutics (RNAC) Stock Price Today?
The Cartesian Therapeutics stock price today is 7.360 USD.
What Stock Exchange Does Cartesian Therapeutics Trade On?
Cartesian Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cartesian Therapeutics?
The stock symbol for Cartesian Therapeutics is "RNAC."
What Is the Cartesian Therapeutics Market Cap?
As of today, Cartesian Therapeutics market cap is 220.360M USD.
What Is Cartesian Therapeutics's Earnings Per Share (TTM)?
The Cartesian Therapeutics EPS (TTM) is -5.794.
When Is the Next Cartesian Therapeutics Earnings Date?
Cartesian Therapeutics will release its next earnings report on Aug 06, 2026.
From a Technical Analysis Perspective, Is RNAC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Cartesian Therapeutics Stock Split?
Cartesian Therapeutics has split 1 times.
How Many Employees Does Cartesian Therapeutics Have?
Cartesian Therapeutics has 75 employees.
What is the current trading status of Cartesian Therapeutics (RNAC)?
As of Jul 30, 2026, Cartesian Therapeutics (RNAC) is trading at a price of 7.360 USD, with a previous close of 7.420 USD. The stock has fluctuated within a day range of 7.360 USD to 7.576 USD, while its 52-week range spans from 5.600 USD to 13.210 USD.
What Is Cartesian Therapeutics (RNAC) Price Target According to Analysts?
The average 12-month price target for Cartesian Therapeutics is 34.571 USD, with a high estimate of 44 USD and a low estimate of 16 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +369.72% Upside potential.
What Is the RNAC Premarket Price?
RNAC's last pre-market stock price is 8.000 USD. The pre-market share volume is 210.000, and the stock has decreased by 0.580, or 7.820%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.